Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2007)
25 slides from Cyclopharm's shareholder meeting presentation, May 9, 2007
Slide 1: Cyclopharm Limited Annual General Meeting
Cyclopharm Limited Annual General Meeting 8 May 2007
Slide 2: Chairman's Welcome
Chairman’s Welcome Welcome to the inaugural Annual General Meeting of Cyclopharm Limited
Slide 3: Agenda
Agenda cyc Nuclear Medicine Managing Director's Review Business Question Time Close
Slide 4: Mission
Mission cyc Nuclear Medicine Our aim is to be the leading nuclear medicine company in the region
Slide 5: Nuclear Medicine
Nuclear Medicine cyc Nuclear Medicine relies on diagnostic radiotracers to detect and monitor various disease states for oncology, cardiology and neurology. Key characteristics: Non invasive (provides a view of the “inside” without surgery) Safe, painless, cost effective Provides information on majo
Slide 6: Molecular Imaging
Molecular Imaging cyc Nuclear medicine is experiencing significant growth driven by PET Positron Emission Tomography (“PET”) allows physicians to differentiate between healthy and diseased tissue and therein: Detect cancer more accurately Detect cancer earlier than conventional methods Identify the
Slide 7: Molecular Imaging: Cyclopharm Developments
Molecular Imaging Nuclear Medicine Cyclopharm Developments Advanced stage of securing first 2 of 3 production centre locations
Slide 8: Molecular Imaging: Industry Developments
Molecular Imaging Industry Developments Industry submission to Government to expand the number of indications for rebate Major industry participants developing molecular imaging strategies Cyclopharm’s PET central pharmacy to contribute to industry growth
Slide 9: Molecular Imaging: Industry Developments
Molecular Imaging Nuclear Med Industry Developments Significant PET / CT camera growth is expected Cyclopharm expect growth in PET procedures to follow US and European trends of over 100% growth annually* *Based on published data over the 2000 — 2005 period
Slide 10: 2006 Financial Highlights
2006 Financial Highlights cyclor og ¥ Nuclear Medicine Sales increased 17% to a record one $10.3m me NPAT up 28% to $2.0m EPS up 28% Cash receipts up 24% Expenses up 3%
Slide 11: 2006 Performance against Prospectus Forecast
2006 Performance against eyclooharm Prospectus Forecast Ne Mee Year ending 31 December 2006 Prospectus Sales Revenue 9,688 EBITDA 2,672 EBIT 2,600 NPAT 2,080 Overall results in line with forecast
Slide 12: Annual Financial Summary
Annual Financial Summary Nuclear Medicine Year ending 31 December 2006 2005 (a) 2006 (a) Sales Revenue 8,806 10,332 EBITDA 2,801 2,724 EBIT 2,722 2,626 NPAT 1,582 2,028 Strong annual sales growth Positioned for regional growth
Slide 13: Q1 2007 Result
Q1 2007 Result GYGIC Nuclear Medicine TechnegasPlus generator sales and Smail User Package strategy successfully implemented Patient Administration Set (PAS) Sales impacted by timing of orders in Europe ‘2008. Group, Generator Sales Group, PAS Sales
Slide 14: Comment on Year End Forecast
Comment on Year End Forecast Nuclear Med Sales expected to return to forecast levels by year end Costs being managed
Slide 15: Business Initiatives: New Drug Application
Business Initiatives New Drug Application Patient enrollment has been slow Management decision to submit new drug application to the FDA in 2007 Sales to the US planned in late 2008
Slide 16: Business Initiatives: Acquisitions
Business Initiatives Nuclear Medicine Acquisitions Our aim is to be the leading nuciear medicine company in the region Altractive businesses include those that will allow Cyclopharm to create a comprehensive suite of radiopharmaceuticals Acquisitions will be actively pursued
Slide 17: Business Initiatives: United Kingdom and Italy
Business Initiatives Nuclear Med United Kingdom Signed an agreement with Qados a key distributor in Europe to sell 300 boxes of PAS in 2007 with increasing volumes thereafter Expected growth of PAS of 150% in 2007 ltaly Registration expected in the H2 2007
Slide 18: Business Initiatives: Latin America
Business Initiatives Nuclear Med Latin America Small User package introduced to access Argentina, Venezuela and Mexico Pursuing regulatory approval in Brazil which has 350 Nuclear Medicine Sites - approval delayed until H2 2007
Slide 19: Business Initiatives: Middle East
Business Initiatives Nuclear Med Middle East Market Share in Kuwait 90%, Oman 50%, Tunisia 40% Libya, Egypt and lran targeted with Small User Package
Slide 20: Business Initiatives: Asia
Business Initiatives Asia Budgeted increase of PAS sales of 300% to China Government signaling privatization of radiopharmaceutical manufacturing Opportunities for PET central pharmacies
Slide 21: Business Initiatives: Thrombotrace
Business Initiatives Nuclear Med Thrombotrace New proposal put forward by the Australian National University Old program discontinued
Slide 22: Conclusion
Conclusion Business objectives for 2007 are aggressive We have several substantial opportunities on which to capitalise We are well placed to become the leading radiopharmaceutical company in the region Radiopharmaceéuticals improve the quality of life for people afflicted with life threatening dise
Slide 23: Agenda
cu 100 a: Ag e n d a ; Nuclear Medicine Managing Director's Review Business Question Time Close
Slide 24: Agenda
cu 100 a: Ag e n d a ; Nuclear Medicine Managing Director's Review Business Question Time Close
Slide 25: Agenda
cu 100 a: Ag e n d a ; Nuclear Medicine Managing Director’s Review Business Question Time Close